Ivermectin

Ivermectin (MK-933) is an activator of glutamate-gated chloride channels (GluCls) with antiparasitic activity.

Ivermectin B1a monosaccharide is produced by selective hydrolysis of the terminal saccharide unit of ivermectin. It can inhibit nematode larval development, but does not cause paralytic activity. This compound has been used as a probe to detect some types of ivermectin resistance.

Ivermectin B1b is the minor component and produces antiparasitic activity by binding to glutamate-gated chloride channels expressed on nematode neurons and pharyngeal muscle cells, inducing irreversible channel opening and very long-lasting hyperpolarization/depolarization of the neuron/muscle cell, thereby blocking further function.

Ivermectin B1a is the major (80%) component of commercially available ivermectin and a derivative of Avermectin B1a.

Ivermectin B1a aglycone is a degradation product generated by acid hydrolysis of the disaccharide structure of ivermectin. It inhibits the growth and development of nematode larvae without causing paralytic effects.

epi-Ivermectin B1a is a significant impurity related to Ivermectin, typically found as a process-related impurity or potential degradation product in antiparasitic formulations. It is also utilized in research on both in vivo and in vitro parasites in cattle.

Deuterated ivermectin B1a

2,3-Dehydro-3,4-dihydro ivermectin, an ivermectin analog and anthelmintic, demonstrates efficacy against L. amazonensis promastigotes and amastigotes, with IC50 values of 13.8 µM and 3.6 µM, respectively, while maintaining a low cytotoxicity profile in macrophages (IC50 = 65.5 µM).

Ivermectin in Acetonitrile (Standard) is a standard material used for research and analysis of Ivermectin. Ivermectin is an antiparasitic compound effective against parasitic infections.

Ivermectin B1a-d2-1 is the deuterium-labeled form of Ivermectin B1a. As a derivative of Avermectin B1a, Ivermectin B1a constitutes the primary component of Ivermectin. Ivermectin (MK-933) is a broad-spectrum antiparasitic agent and is also being considered as a candidate active molecule in the treatment of SARS-CoV-2/COVID-19.

Doramectin (Dectomax) is an antiparasitic agent.

Selamectin (UK-124114) is a macrocyclic lactone derivative of ivermectin, an anthelmintic that potentiates glutamate- and GABA-gated chloride channel opening in nematodes. In an H. contortus larval development assay, selamectin (0.1 μg/ml) shows the effect of growth inhibition.

UK-124114 (Selamectin) is a macrocyclic lactone derivative of ivermectin, an anthelmintic that potentiates glutamate- and GABA-gated chloride channel opening in nematodes. In an H. contortus larval development assay, selamectin (0.1 μg/ml) shows the effect of growth inhibition.

SDH-IN-43 (Compound i-19) is a succinate dehydrogenase (SDH) inhibitor. It exhibits potent inhibitory activity against Caenorhabditis elegans, with an IC50 value of 6.67 μM. SDH-IN-43 significantly reduces the reproductive and locomotor abilities of C. elegans and is effective against strains resistant to Levamisole, Benzimidazole, and Ivermectin. This compound is applicable for research on parasitic infections.

Imidacloprid impurity 1-d4 is the deuterium-labeled version of Imidacloprid impurity 1. Imidacloprid impurity 1 (IMP-2) is identified as an impurity that arises during the synthesis of Ivermectin.